BofA raised the firm’s price target on Metsera (MTSR) to $45 from $38 and keeps a Buy rating on the shares after the company announced the first round of clinical data on its amylin agonist, MET-233i. The firm views the data as competitive and “partially de-risking” to the program. It upped its probability of success for MET-233i to 45% from 30%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera, Inc.: Buy Rating Affirmed Amid Promising Clinical Data and Strategic Positioning
- Metsera initiated with Early-Stage Biotech at Goldman Sachs
- Circle initiated, Charter upgraded: Wall Street’s top analyst calls
- Metsera initiated with an Overweight at Wells Fargo
- Metsera price target raised to $62 from $56 at Guggenheim